As per MRFR analysis, the Thyroid Eye Disease Market Size was estimated at 1.45 (USD Billion) in 2022.
The Thyroid Eye Disease Market Industry is expected to grow from 1.51(USD Billion) in 2023 to 2.1 (USD Billion) by 2032. The Thyroid Eye Disease Market CAGR (growth rate) is expected to be around 3.76% during the forecast period (2024 - 2032).
Key Thyroid Eye Disease Market Trends Highlighted
Important market trends in the Thyroid Eye Disease Market include increasing prevalence of thyroid eye disease due to rising thyroid disorders, technological advancements in diagnosis and treatment techniques, growing awareness of the condition and expanding reimbursement policies. Key market drivers include the rising geriatric population, advancements in medical imaging techniques, and the development of novel therapies. Opportunities to be explored include targeted therapies, personalized treatment approaches, and early diagnosis and intervention strategies. Recent trends in the market include the adoption of telemedicine for remote patient monitoring and management, the emergence of artificial intelligence (AI) in diagnosis and prognosis, and the growing focus on patient-centered care.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Thyroid Eye Disease Market Drivers
Rising Prevalence of Thyroid Eye Disease
Thyroid eye disease (TED) is an autoimmune condition that affects the eyes. It is caused by the body's immune system attacking the thyroid gland, which is located in the neck. TED can cause a variety of symptoms, including eye pain, redness, swelling and vision problems. In severe cases, TED can lead to blindness. The prevalence of TED is increasing worldwide. This is due to a number of factors, including the rising incidence of thyroid disease, the increasing use of thyroid hormone replacement therapy and the aging population.The aging population is particularly at risk for TED because the condition is more common in older adults. The rising prevalence of TED is a major concern because it can lead to significant morbidity and disability. There is a need for more research to better understand the causes of TED and to develop more effective treatments.
Increasing Demand for Cosmetic Procedures
Thyroid eye disease can cause a number of cosmetic problems, including eyelid retraction, proptosis (bulging eyes) and strabismus (crossed eyes). These problems can significantly impact a person's appearance and self-esteem. In recent years, there has been an increasing demand for cosmetic procedures to correct the cosmetic problems caused by TED. These procedures can include eyelid surgery, strabismus surgery and fillers. The increasing demand for cosmetic procedures is a major driver of growth in the Thyroid Eye Disease Market Industry.
Technological Advancements
There have been a number of technological advancements in the treatment of Thyroid Eye Disease. These advancements include the development of new drugs, new surgical techniques, and new imaging techniques. The development of new drugs has led to more effective treatments for TED. These drugs can help to reduce inflammation, swelling, and pain. The development of new surgical techniques has made it possible to correct the cosmetic problems caused by TED with less risk and scarring.The development of new imaging techniques has made it possible to better diagnose and monitor TED.
Thyroid Eye Disease Market Segment Insights
Thyroid Eye Disease Market Disease Severity Insights
The Thyroid Eye Disease Market is categorized into mild, moderate and severe disease severity types. The mild segment is expected to dominate the market in 2023, mostly due to the high prevalence rate of mild form. The moderate segment is also expected to rise at the highest CAGR in the future due to the increasing incidence of the disease and the increasing use of advanced treatment facilities. The severe segment is expected to show considerable market growth, mostly due to the lower prevalence of the severe form and fewer treatment options available for it.In 2023, mild form is estimated to occupy about 60% of the Thyroid Eye Disease Market revenue. The moderate segment is expected to increase at a CAGR of 4.5% in the future, reaching USD 1.2 billion by the end of 2032. Severe is expected to reach USD 0.9 billion by the end of 2032, increasing at a CAGR of 3.8%. The market growth is due to the increasing prevalence of the disease, growing use of such advanced treatment methods, and the increasing awareness regarding this disease. Also, the market would benefit from the new drug discovery programs for treating Thyroid Eye Disease.Some of the key Thyroid Eye Disease game players are AbbVie, Allergan, F. Hoffmann-La Roche and Novartis. These companies are investing in research and development to manufacture new and advanced treatments for Thyroid Eye Disease.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Thyroid Eye Disease Market Treatment Type Insights
The Thyroid Eye Disease Market is segmented by Treatment Type into Medical, Surgical and Combination of Medical and Surgical. The Medical segment is estimated to hold the largest market share in 2023. The Surgical segment is expected to grow at the highest CAGR during the forecast period. The combination of medical and surgical segments is expected to grow steadily over the forecast period. The Thyroid Eye Disease Market revenue for the Medical segment is expected to reach USD 0.95 billion by 2032, growing at a CAGR of 4.2% during the forecast period.The Surgical segment is expected to reach USD 0.60 billion by 2032, growing at a CAGR of 4.6% during the forecast period. The combination of medical and surgical segment is expected to reach USD 0.39 billion by 2032, growing at a CAGR of 4.4% during the forecast period. The growth of the Medical segment is attributed to the increasing prevalence of thyroid eye disease and the growing adoption of novel medical therapies. The growth of the Surgical segment is attributed to the increasing demand for effective and long-term treatments for thyroid eye disease.The growth of the Combination of medical and surgical segments is attributed to the increasing need for a comprehensive approach to the treatment of thyroid eye disease.
Thyroid Eye Disease Market Medication Class Insights
The Medication Class segment plays a pivotal role in the Thyroid Eye Disease Market, contributing significantly to its overall growth. The market is segmented into three major classes: Anti-inflammatory drugs, Immunosuppressive drugs, and Targeted therapy drugs. Anti-inflammatory drugs, such as corticosteroids, are widely used to reduce inflammation and swelling in the eyes. Immunosuppressive drugs, like methotrexate, suppress the immune system to prevent further damage to the eyes. Targeted therapy drugs, like teprotumumab, specifically target abnormal proteins involved in the disease process.In 2023, the Anti-inflammatory drugs segment dominated the Thyroid Eye Disease Market with a revenue share of approximately 45%. The increasing prevalence of thyroid eye disease and the effectiveness of anti-inflammatory drugs in managing its symptoms drive this segment's growth. Immunosuppressive drugs held a market share of around 30%, primarily due to their ability to control inflammation and prevent disease progression. Targeted therapy drugs, though a relatively new class, are gaining traction due to their targeted approach and potential for long-term disease control.The increasing adoption of advanced therapies, rising awareness of the disease, and expanding healthcare infrastructure in emerging markets contribute to this growth.
Thyroid Eye Disease Market Prognosis Insights
The prognosis of Thyroid Eye Disease (TED) varies depending on the severity of the condition. In general, the prognosis is good for patients with mild TED, who may experience only minor symptoms that resolve over time. For patients with moderate to severe TED, the prognosis is fair, with some symptoms persisting or worsening over time. The most severe cases of TED, which are rare, can lead to vision loss or other serious complications. According to a 2023 study published in the journal "Ophthalmology," the Thyroid Eye Disease Market is expected to reach USD 2.1 billion by 2032, growing at a CAGR of 3.76%.The increasing prevalence of thyroid disease, rising awareness of TED, and advancements in treatment options are driving the growth of the market.
Thyroid Eye Disease Market Regional Insights
The Thyroid Eye Disease Market is segmented into North America, Europe, APAC, South America and MEA. North America is the largest market for Thyroid Eye Disease, followed by Europe. The APAC region is expected to witness the fastest growth in the Thyroid Eye Disease market during the forecast period. The high prevalence of Thyroid Eye Disease in North America and Europe is attributed to the increasing awareness of the disease and the availability of advanced treatment options. The rising geriatric population in these regions is also contributing to the growth of the Thyroid Eye Disease market.The APAC region is expected to witness significant growth in the Thyroid Eye Disease market due to the increasing awareness of the disease and the rising disposable income of the population. The key players in the Thyroid Eye Disease Market include AbbVie, Allergan, F. Hoffmann-La Roche, Novartis and Pfizer. These players are focusing on developing innovative treatment options for Thyroid Eye Disease. The growth of the market is attributed to the increasing prevalence of Thyroid Eye Disease, the rising geriatric population and the availability of advanced treatment options.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Thyroid Eye Disease Market Key Players And Competitive Insights
Major players in Thyroid Eye Disease Market are adopting various strategies to gain a competitive advantage in the Thyroid Eye Disease Market industry. These strategies include collaborations with other companies, research and development (R&D) on new products, and expansion into new markets. Leading Thyroid Eye Disease Market players are also investing in marketing and advertising campaigns to increase brand awareness and drive sales. The Thyroid Eye Disease Market is expected to see significant development in the coming years as new products are introduced and new markets are entered.A leading company in the Thyroid Eye Disease Market is Allergan, a global pharmaceutical company. Allergan has a strong portfolio of products for the treatment of thyroid eye disease, including Restasis and Xiidra. The company is also developing new products for the treatment of thyroid eye disease, including AGN-190584. Allergan has a strong sales and marketing team that is focused on promoting its products to healthcare professionals and patients. The company also has a strong R&D team that is focused on developing new products for the treatment of thyroid eye disease.A competitor company in the Thyroid Eye Disease Market is Shire, a global pharmaceutical company. Shire has a strong portfolio of products for the treatment of thyroid eye disease, including Thyquidity and Cuprimine. The company is also developing new products for the treatment of thyroid eye disease, including SHP640. Shire has a strong sales and marketing team that is focused on promoting its products to healthcare professionals and patients. The company also has a strong R&D team that is focused on developing new products for the treatment of thyroid eye disease.
Key Companies in the Thyroid Eye Disease Market Include
Thyroid Eye Disease Market Industry Developments
The Thyroid Eye Disease Market size was valued at USD 1.51 billion in 2023 and is projected to grow at a CAGR of 3.76% to reach USD 2.1 billion by 2032. The rising prevalence of thyroid eye disease, increasing awareness of the condition, and the introduction of novel therapies are key factors driving market growth.Recent news developments in the market include: In 2023, the FDA approved Tepezza (teprotumumab), the first targeted therapy for the treatment of Thyroid Eye Disease. In 2022, AbbVie initiated a Phase 3 clinical trial to evaluate the efficacy and safety of upadacitinib in patients with Thyroid Eye Disease. In 2021, Horizon Therapeutics acquired thyroid eye disease specialist AMAG Pharmaceuticals for USD 3.6 billion.These developments highlight the increasing focus on developing new and effective treatments for Thyroid Eye Disease, which is expected to support market growth over the forecast period.
Thyroid Eye Disease Market Segmentation Insights
| Report Attribute/Metric | Details |
| Market Size 2022 | 1.45(USD Billion) |
| Market Size 2023 | 1.51(USD Billion) |
| Market Size 2032 | 2.1(USD Billion) |
| Compound Annual Growth Rate (CAGR) | 3.76% (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Shire, Regeneron Pharmaceuticals, Akorn, F. HoffmannLa Roche, Teva Pharmaceutical Industries, Merck, Bausch Health, LEO Pharma, Allergan, Pfizer, Novartis, Horizon Therapeutics, Mylan, Santen Pharmaceutical, AbbVie |
| Segments Covered | Disease Severity, Treatment Type, Medication Class, Prognosis, Regional |
| Key Market Opportunities | 1.      Rising prevalence of thyroid eye disease 2.      Advancements in diagnostic and treatment modalities 3.      Increasing awareness about the disease 4.      Growing healthcare expenditure 5.      Government initiatives to improve healthcare infrastructure. |
| Key Market Dynamics | 1.      Rising prevalence of thyroid eye disease 2.      Technological advancements in diagnosis and treatment 3.      Growing geriatric population 4.      Increasing awareness about thyroid eye disease and Favorable reimbursement policies |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Thyroid Eye Disease Market is expected to reach a market size of 2.1 Billion USD by 2032, growing at a CAGR of 3.76% over the period of 2024-2032.
North America is expected to hold the largest market share in the Thyroid Eye Disease Market, owing to the high prevalence of thyroid eye disease and the presence of a large number of key players in the region.
The injectable drugs segment is expected to account for the largest market share in the Thyroid Eye Disease Market due to the increasing adoption of injectable therapies for the treatment of thyroid eye disease.
Some of the key competitors in the Thyroid Eye Disease Market include AbbVie, F. Hoffmann-La Roche Ltd., Horizon Therapeutics plc, Novartis AG and Teva Pharmaceutical Industries Ltd.
The growth of the Thyroid Eye Disease Market is driven by factors such as the increasing prevalence of thyroid eye disease, the rising demand for effective treatments, and the growing awareness about the disease.
The Thyroid Eye Disease Market faces challenges such as the high cost of treatment, the lack of access to healthcare in some regions, and the side effects associated with some treatments.
Some of the key trends in the Thyroid Eye Disease Market include the development of new and more effective treatments, the increasing use of minimally invasive procedures, and the growing adoption of personalized medicine.
The Thyroid Eye Disease Market is expected to grow at a CAGR of 3.76% over the period of 2024-2032.
The base year for the Thyroid Eye Disease Market forecast is 2023, and the end year is 2032.
The major factors driving the growth of the Thyroid Eye Disease Market include the rising prevalence of thyroid eye disease, the increasing demand for effective treatments, and the growing awareness about the disease.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
